Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     



This item requires a subscription to Neurology Online.
Cover Full Text
Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis
Dorsey et al. Neurology.2007; 68: 1524-1528
To view this item, select one of the options below:
* Sign In
* Sign in without cookies.

* Can't get past this page?

* Help with Cookies.

* Need to Activate?
Forgot your user name or password?
* Purchase Short-Term Access
* Pay per Article - You may access this article (from the computer you are currently using) for 1 day for US$20.00.
* Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
* Sign Up
* Subscribe to the Journal - Subscribe to the print and/or online journal.
This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dorsey, E. R.
Right arrow Articles by Schwid, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dorsey, E. R.
Right arrow Articles by Schwid, S. R.
Related Collections
Right arrow All Immunology
Right arrow Autoimmune diseases
Right arrow All Clinical trials
Right arrow Multiple sclerosis

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by AAN Enterprises, Inc.